Antiretroviral Drugs Market : By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRT?s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Antiretroviral Drugs Market size was valued at USD 62.9 billion in 2022, growing at a CAGR of 3.6% during the forecast period 2023-29. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases. Globally antiviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the global Anti-retroviral Drugs Market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs. Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share.

Antiretroviral Drugs Market Key Developments :

In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb?s late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases.

For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.

In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline?s joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.  

 

Global Antiretroviral Drugs Market Summary

Study Period

2023-29

Base Year

2022

CAGR

3.6%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Antiretroviral Drugs Market Dynamics

However, as viral illnesses such as HIV, Herpes, Influenza, and others become more common, demand for antiviral drugs is likely to rise over the forecast period. According to UNAIDS, more than 37 million people around the world would be living with HIV by 2020. In 2020, around 1.5 million more people will have contracted HIV. Overall, the COVID-19 pandemic has greatly improved market growth in 2020, however the pandemic has had a negative influence on other antiviral drug applications. Over the predicted period, a primary element driving demand for antiviral medications is the rising incidence of viral illness over the world. According to the WHO, an estimated 325 million individuals worldwide have hepatitis, with 71 million of these having chronic hepatitis C virus infection. Furthermore, the United States Department of Health and Human Services estimates that 2.4 million people in the country have hepatitis C, with roughly 850,000 people infected with hepatitis B. The global need for antiviral medications is expected to rise as the number of patients grows.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Antiretroviral Drugs Market Segmentation

By drug class
  • Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
  • Protease Inhibitors
  • Integrate Inhibitors
  • Fusion Inhibitors
  • Chemokine Receptor Inhibitors
  • Others
By Administration
  • Oral
  • Parenteral
By Distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
By Geography

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive summary
  2. Global Antiretroviral Drugs Market Introduction

2.1. Global Antiretroviral Drugs Market ? Taxonomy 2.2. Global Antiretroviral Drugs Market ?Definitions 2.2.1. Drug Class 2.2.2. Route of Administration 2.2.3. Distribution Channel

  1. Global Antiretroviral Drugs Market Dynamics

3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Antiretroviral Drugs Market Dynamics ? Factors Impact Analysis 3.6. Global Antiretroviral Drugs Market ? Regulations 3.6.1. U.S 3.6.2. Europe 3.6.3. Japan 3.6.4. China 3.7. Global Antiretroviral Drugs Market ? Product Innovations

  1. Global Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 ? 2024

4.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market Oppurtunity Analysis

  1. Global Antiretroviral Drugs Market, By Drug Class, 2013 - 2017 and Forecast, 2018 - 2024

5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 5.1.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.3. Market Opportunity Analysis 5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 5.2.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.3. Market Opportunity Analysis 5.3. Protease Inhibitors 5.3.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.3.3. Market Opportunity Analysis 5.4. Integrate Inhibitors 5.4.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.4.3. Market Opportunity Analysis 5.5. Fusion Inhibitors 5.5.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.5.3. Market Opportunity Analysis 5.6. Chemokine Receptor Inhibitors 5.6.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.6.3. Market Opportunity Analysis 5.7. Others 5.7.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.7.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Route of Administration, 2013 - 2017 and Forecast, 2018 - 2024

6.1. Parenteral 6.1.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.1.3. Market Opportunity Analysis 6.2. Oral 6.2.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.2.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Distribution Channel , 2013 - 2017 and Forecast, 2018 - 2024

7.1. Retail Pharmacies 7.1.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.1.3. Market Opportunity Analysis 7.2. Hospital Pharmacies 7.2.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.2.3. Market Opportunity Analysis 7.3. Online Pharmacies 7.3.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.3.3. Market Opportunity Analysis 7.4. Others 7.4.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.4.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024

8.1. North America 8.1.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.1.3. Market Opportunity Analysis 8.2. Europe 8.2.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.2.3. Market Opportunity Analysis 8.3. Asia-Pacific 8.3.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.3.3. Market Opportunity Analysis 8.4. Latin America 8.4.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.4.3. Market Opportunity Analysis 8.5. Middle East and Africa 8.5.1. Market Analysis, 2013 ? 2017 and Forecast, 2018 ? 2024 (Revenue, USD Mn) 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.5.3. Market Opportunity Analysis 8.6. Global Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2018 ? 2024

  1. North America Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024

9.1. Drug Class Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 9.1.3. Protease Inhibitors 9.1.4. Integrate Inhibitors 9.1.5. Fusion Inhibitors 9.1.6. Chemokine Receptor Inhibitors 9.1.7. Others 9.2. Route of Administration Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.2.1. Parenteral 9.2.2. Oral 9.3. Distribution Channel Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.3.1. Retail Pharmacies 9.3.2. Hospital Pharmacies 9.3.3. Online Pharmacies 9.3.4. Others 9.4. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 9.4.1. U.S. 9.4.2. Canada 9.5. North America Antiretroviral Drugs Market - Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 ? 2024 9.6. North America Antiretroviral Drugs Market Dynamics ? Trends

  1. Europe Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024

10.1. Drug Class Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 10.1.3. Protease Inhibitors 10.1.4. Integrate Inhibitors 10.1.5. Fusion Inhibitors 10.1.6. Chemokine Receptor Inhibitors 10.1.7. Others 10.2. Route of Administration Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.2.1. Parenteral 10.2.2. Oral 10.3. Distribution Channel Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.3.1. Retail Pharmacies 10.3.2. Hospital Pharmacies 10.3.3. Online Pharmacies 10.3.4. Others 10.4. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.4.1. Germany 10.4.2. UK 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Russia 10.4.7. Poland 10.4.8. Rest of Europe 10.5. Europe Antiretroviral Drugs Market - Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 ? 2024 10.6. Europe Antiretroviral Drugs Market Dynamics ? Trends

  1. Asia-Pacific Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024

11.1. Drug Class Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 11.1.3. Protease Inhibitors 11.1.4. Integrate Inhibitors 11.1.5. Fusion Inhibitors 11.1.6. Chemokine Receptor Inhibitors 11.1.7. Others 11.2. Route of Administration Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.2.1. Parenteral 11.2.2. Oral 11.3. Distribution Channel Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.3.1. Retail Pharmacies 11.3.2. Hospital Pharmacies 11.3.3. Online Pharmacies 11.3.4. Others 11.4. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.4.1. Japan 11.4.2. China 11.4.3. India 11.4.4. ASEAN 11.4.5. Australia & New Zealand 11.4.6. Rest of Asia-Pacific 11.5. Asia-Pacific Antiretroviral Drugs Market - Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 ? 2024 11.6. Europe Antiretroviral Drugs Market Dynamics ? Trends

  1. Latin America Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024

12.1. Drug Class Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 12.1.3. Protease Inhibitors 12.1.4. Integrate Inhibitors 12.1.5. Fusion Inhibitors 12.1.6. Chemokine Receptor Inhibitors 12.1.7. Others 12.2. Route of Administration Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.2.1. Parenteral 12.2.2. Oral 12.3. Distribution Channel Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.3.1. Retail Pharmacies 12.3.2. Hospital Pharmacies 12.3.3. Online Pharmacies 12.3.4. Others 12.4. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Argentina 12.4.4. Venezuela 12.4.5. Rest of Latin America 12.5. Latin America Antiretroviral Drugs Market - Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 ? 2024 12.6. Latin America Antiretroviral Drugs Market Dynamics ? Trends

  1. Middle East and Africa Antiretroviral Drugs Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024

13.1. Drug Class Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) 13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) 13.1.3. Protease Inhibitors 13.1.4. Integrate Inhibitors 13.1.5. Fusion Inhibitors 13.1.6. Chemokine Receptor Inhibitors 13.1.7. Others 13.2. Route of Administration Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.2.1. Parenteral 13.2.2. Oral 13.3. Distribution Channel Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.3.1. Retail Pharmacies 13.3.2. Hospital Pharmacies 13.3.3. Online Pharmacies 13.3.4. Others 13.4. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.4.1. Brazil 13.4.2. Mexico 13.4.3. Argentina 13.4.4. Venezuela 13.4.5. Rest of Latin America 13.5. Country Analysis (2013 ? 2017) and Forecast (2018 ? 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.5.1. Gulf Cooperation Council (GCC) Countries 13.5.2. Israel 13.5.3. South Africa 13.5.4. Rest of MEA 13.6. MEA Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 ? 2024 13.7. MEA Antiretroviral Drugs Market Dynamics ? Trends

  1. Competition Landscape

14.1. Strategic Dashboard of Top Market Players 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 14.2.1. Abbott Laboratories (U.S.) 14.2.2. AstraZeneca plc (U.K.) 14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S) 14.2.4. Gilead Sciences (U.S.) 14.2.5. GlaxoSmithKline Plc (U.K.) 14.2.6. F. Hoffmann-La Roche AG (Switzerland)

  1. Research Methodology
  2. Key Assumptions and Acronyms
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy?s Laboratories Ltd.